UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
(Amendment No. 1)*
Under the Securities Exchange Act of 1934
| X4 PHARMACEUTICALS, INC. |
| (Name of Issuer) |
|
|
| Common Stock |
| (Title of Class of Securities) |
|
|
| 98420X103 |
| (CUSIP Number) |
|
|
| March 23, 2021 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 98420X103 | SCHEDULE 13G | Page 2 of 8 Pages |
| 1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
OrbiMed Advisors LLC | |||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o |
|||
| 3 |
SEC USE ONLY
| |||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 |
SOLE VOTING POWER
0 | ||
| 6 |
SHARED VOTING POWER
1,835,993(1) | |||
| 7 |
SOLE DISPOSITIVE POWER
0 | |||
| 8 |
SHARED DISPOSITIVE POWER
1,835,993(1) | |||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,835,993(1) | |||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
|
o | ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.6%(2) | |||
| 12 |
TYPE OF REPORTING PERSON (See Instructions)
IA | |||
(1) Includes (i) 1,373,493 outstanding shares of common stock, par value $0.001 per share (the “Shares”), of X4 Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”), and (ii) 462,500 Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”).
(2) This percentage is calculated based upon 17,384,478 Shares outstanding of the Issuer, as set forth in the Issuer’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 19, 2021, and giving effect to an additional (i) 6,271,836 Shares issued and sold by the Issuer to certain investors in a private placement, as set forth in the Issuer’s Form 8-K filed with the SEC on March 19, 2021, which closed on March 23, 2021, and (ii) 462,500 Shares subject to currently exercisable Warrants held by the Reporting Persons.
| CUSIP No. 98420X103 | SCHEDULE 13G | Page 3 of 8 Pages |
| 1 |
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
OrbiMed Capital GP IV LLC | |||
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) o (b) o |
|||
| 3 |
SEC USE ONLY
| |||
| 4 |
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH |
5 |
SOLE VOTING POWER
0 | ||
| 6 |
SHARED VOTING POWER
1,835,993(1) | |||
| 7 |
SOLE DISPOSITIVE POWER
0 | |||
| 8 |
SHARED DISPOSITIVE POWER
1,835,993(1) | |||
| 9 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,835,993(1) | |||
| 10 |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
|
o | ||
| 11 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.6%(2) | |||
| 12 |
TYPE OF REPORTING PERSON (See Instructions)
OO | |||
(1) Includes (i) 1,373,493 outstanding shares of common stock, par value $0.001 per share (the “Shares”), of X4 Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”), and (ii) 462,500 Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”).
(2) This percentage is calculated based upon 17,384,478 Shares outstanding of the Issuer, as set forth in the Issuer’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 19, 2021, and giving effect to an additional (i) 6,271,836 Shares issued and sold by the Issuer to certain investors in a private placement, as set forth in the Issuer’s Form 8-K filed with the SEC on March 19, 2021, which closed on March 23, 2021, and (ii) 462,500 Shares subject to currently exercisable Warrants held by the Reporting Persons.
| CUSIP No. 98420X103 | SCHEDULE 13G | Page 4 of 8 Pages |
| Item 1. | (a) Name of Issuer: |
X4 Pharmaceuticals, Inc.
| (b) Address of Issuer’s Principal Executive Offices: |
61 North Beacon Street, 4th Floor
Boston, Massachusetts 02134
| Item 2. | (a) Name of Person Filing: |
This Schedule 13G is being filed by OrbiMed Advisors LLC (“Advisors”), a limited liability company organized under the laws of Delaware, and OrbiMed Capital GP IV LLC (“GP IV”), a limited liability company organized under the laws of Delaware (collectively, the “Reporting Persons”).
See Exhibit A for the Reporting Persons’ agreement for a joint filing of a single statement on their behalf.
| (b) Address of Principal Business Office: |
601 Lexington Avenue, 54th Floor
New York, NY 10022
| (c) Citizenship: |
Please refer to Item 4 on each cover sheet for each filing person.
| (d) Title of Class of Securities: |
Common Stock
| (e) CUSIP No.: |
98420X103
| Item 3. |
Not Applicable
| CUSIP No. 98420X103 | SCHEDULE 13G | Page 5 of 8 Pages |
Item 4. Ownership:
GP IV is the general partner of OrbiMed Private Investments IV, LP (“OPI IV”), which holds 1,835,993 shares of common stock of the Issuer (“Shares”), which includes 462,500 Shares subject to currently exercisable warrants to purchase Shares held by the Reporting Persons. Advisors is an investment advisor in accordance with Rule 13d-1(b)(1)(ii)(E) under the Securities Exchange Act of 1934, as amended, and is the managing member of GP IV. As a result, Advisors and GP IV share the power to direct the vote and the disposition of the Shares held of record by OPI IV. Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein. On the basis of these relationships, GP IV and Advisors may be deemed to share beneficial ownership of the Shares held by OPI IV.
(a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b) Percent of class: See the response(s) to Item 11 on the attached cover page(s).
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5. Ownership of Five Percent or Less of a Class.
Not Applicable.
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
See Item 4.
Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable.
Item 8. Identification and Classification of Members of the Group.
Not Applicable.
Item 9. Notice of Dissolution of Group.
Not Applicable.
| CUSIP No. 98420X103 | SCHEDULE 13G | Page 6 of 8 Pages |
Item 10. Certification.
By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
| CUSIP No. 98420X103 | SCHEDULE 13G | Page 7 of 8 Pages |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: March 25, 2021
|
OrbiMed Capital GP IV LLC By: OrbiMed Advisors LLC, its Managing Member | |||
| By: | /s/ Jonathan T. Silverstein | ||
| Name: | Jonathan T. Silverstein | ||
| Title: | Member of OrbiMed Advisors LLC | ||
| OrbiMed Advisors LLC | |||
| By: | /s/ Jonathan T. Silverstein | ||
| Name: | Jonathan T. Silverstein | ||
| Title: | Member | ||
| CUSIP No. 98420X103 | SCHEDULE 13G | Page 8 of 8 Pages |
EXHIBIT A
JOINT FILING AGREEMENT
The undersigned hereby agree that this amendment to Schedule 13G dated March 25, 2021 (the “Schedule 13G”), with respect to the Shares of X4 Pharmaceuticals, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to the Schedule 13G. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of March 25, 2021.
|
OrbiMed Capital GP IV LLC By: OrbiMed Advisors LLC, its Managing Member | |||
| By: | /s/ Jonathan T. Silverstein | ||
| Name: | Jonathan T. Silverstein | ||
| Title: | Member of OrbiMed Advisors LLC | ||
| OrbiMed Advisors LLC | |||
| By: | /s/ Jonathan T. Silverstein | ||
| Name: | Jonathan T. Silverstein | ||
| Title: | Member | ||